JP2006528242A - アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態 - Google Patents

アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態 Download PDF

Info

Publication number
JP2006528242A
JP2006528242A JP2006532854A JP2006532854A JP2006528242A JP 2006528242 A JP2006528242 A JP 2006528242A JP 2006532854 A JP2006532854 A JP 2006532854A JP 2006532854 A JP2006532854 A JP 2006532854A JP 2006528242 A JP2006528242 A JP 2006528242A
Authority
JP
Japan
Prior art keywords
compound
hydroxy
water
ethyl
quinolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006532854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528242A5 (cg-RX-API-DMAC7.html
Inventor
サビーヌ アクスト,
ヨアンナ スタージャデス,
Original Assignee
セラヴァンス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス インコーポレーテッド filed Critical セラヴァンス インコーポレーテッド
Publication of JP2006528242A publication Critical patent/JP2006528242A/ja
Publication of JP2006528242A5 publication Critical patent/JP2006528242A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2006532854A 2003-05-08 2004-05-07 アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態 Withdrawn JP2006528242A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46881003P 2003-05-08 2003-05-08
PCT/US2004/014302 WO2004101525A1 (en) 2003-05-08 2004-05-07 Crystalline form of aryl aniline beta-2 adrenergic receptor agonist

Publications (2)

Publication Number Publication Date
JP2006528242A true JP2006528242A (ja) 2006-12-14
JP2006528242A5 JP2006528242A5 (cg-RX-API-DMAC7.html) 2007-06-14

Family

ID=33452233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532854A Withdrawn JP2006528242A (ja) 2003-05-08 2004-05-07 アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態

Country Status (6)

Country Link
US (1) US7060712B2 (cg-RX-API-DMAC7.html)
EP (1) EP1622875B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528242A (cg-RX-API-DMAC7.html)
AT (1) ATE450511T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024383D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004101525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1786762A2 (en) * 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EA200701260A1 (ru) * 2005-01-11 2008-02-28 Глаксо Груп Лимитед Циннаматные соли бета-2 адренергического агониста
GB0512246D0 (en) * 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW200840578A (en) * 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
US20120178762A1 (en) 2006-12-15 2012-07-12 Warner Chilcott Company, Llc Compositions of azimilide dihydrochloride
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9713819D0 (en) 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ グループ リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate

Also Published As

Publication number Publication date
EP1622875B1 (en) 2009-12-02
DE602004024383D1 (de) 2010-01-14
US7060712B2 (en) 2006-06-13
WO2004101525A1 (en) 2004-11-25
US20040224982A1 (en) 2004-11-11
EP1622875A1 (en) 2006-02-08
ATE450511T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
US7772434B2 (en) Crystalline form of a β2 adrenergic receptor agonist
US20050075271A1 (en) Crystalline beta2 adrenergic receptor agonist
CN1910137B (zh) 用作β2肾上腺素能受体激动剂的芳基苯胺衍生物
US7060712B2 (en) Crystalline form of aryl aniline β2 adrenergic receptor agonist
JP4143413B2 (ja) β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
JP2005533868A (ja) アリールエタノールアミンβ2−アドレナリン受容体アゴニスト化合物
JP2007509103A (ja) 医薬化合物
US7772250B2 (en) Compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070424

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100128